The House of Representatives has voted to extend a Department of Defense psychedelics research program by six years and to write portions of President Trump's psychedelics executive order into federal law, folding both measures into the Fiscal Year 2027 National Defense Authorization Act. At the same time, Republican leadership on the House Rules Committee blocked a separate cannabis waiver amendment from even reaching a floor vote, leaving military recruitment policy on marijuana largely frozen in place.
For the cannabis industry, the split outcome is instructive. Federal lawmakers remain willing to expand access pathways for psychedelic-assisted therapy inside a highly regulated research framework, yet they continue to treat marijuana enlistment policy as politically untouchable, even as individual service branches experiment with their own waiver systems. Operators watching federal cannabis policy for signals on descheduling or banking reform shouldn't read too much into the psychedelics provisions; this is a defense authorization bill, not a commerce bill, and the compliance mechanics involved are closer to clinical trial oversight than retail regulation. Still, the contrast matters for anyone tracking how Congress handles Schedule I substances differently depending on political framing. Retailers managing their own compliance logs, batch tracking, and lab testing schedules already know how much daily operational weight sits on getting scheduling and access rules right; dispensaries running on modern retail management software for cannabis understand that regulatory language, however narrow, tends to ripple outward into licensing, testing standards, and eventually retail practice.
What the NDAA Amendments Actually Do
The Luttrell-led amendment extends DOD's psilocybin, MDMA, ibogaine, and 5-MeO-DMT research authorization, first enacted in the 2024 NDAA, from three years of annual progress reporting to nine, with research funding performance extended to September 30, 2033. A second amendment, sponsored by Luttrell, Correa, Rulli, and McCaul, would require the Department of Veterans Affairs to name an official overseeing "emerging therapeutic interventions" within 90 days and to file recurring reports to Congress on ibogaine and related therapies. Neither measure changes the Controlled Substances Act status of these substances; both operate strictly within DOD and VA research and reporting structures, not consumer access.
Why the Marijuana Waiver Amendment Stalled
The blocked Joyce-Titus amendment would have pushed the Air Force, Space Force, and Marine Corps to adopt permanent THC waiver systems already used by the Army and Navy, letting recruits who failed a cannabis toxicology screen reapply for enlistment. Recruitment shortfalls have pushed some branches toward more flexible cannabis policy, but the Rules Committee's decision to keep the amendment off the floor shows how uneven that flexibility remains. In practice, though, this isn't really about tolerance for cannabis use; it's about branch-level personnel policy resisting standardization, even under recruitment pressure.
The Compliance Gap Between Military and Retail Policy
DOD's position on cannabis has not softened. A memo issued this month to Pentagon leadership reaffirmed that marijuana use remains prohibited for service members and civilian employees regardless of state legalization or federal rescheduling efforts, and the Army's "zero-tolerance" stance extends to hemp-derived products, including CBD lotions and hair care items. This creates a compliance environment that runs opposite to state-legal adult-use and medical markets, where product labeling, COA disclosure, and lab-verified THC content are standard consumer protections rather than grounds for disqualification. For wholesalers and brands supplying hemp-adjacent products, the military's blanket restriction is a reminder that federal descheduling, if it happens, won't automatically harmonize workplace drug policy across government agencies.
